MedTrace Logo

Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea

NCT01976650 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 724

Last updated 2016-01-13

Study results available
· View outcomes & findings →

Summary

This study is a Post-Market Surveillance study in Korea to evaluate the safety and efficacy of dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant used to treat Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye in clinical practice.

Conditions

  • Retinal Vein Occlusion

Interventions

DRUG

dexamethasone 700 ㎍ intravitreal implant

dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01976650 on ClinicalTrials.gov